United Therapeutics Corporation $UTHR Shares Sold by Greenwood Capital Associates LLC

Greenwood Capital Associates LLC reduced its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 5.9% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,210 shares of the biotechnology company’s stock after selling 139 shares during the quarter. Greenwood Capital Associates LLC’s holdings in United Therapeutics were worth $635,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. SVB Wealth LLC acquired a new stake in United Therapeutics in the 1st quarter valued at approximately $32,000. Geneos Wealth Management Inc. increased its position in United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 85 shares during the period. Sound Income Strategies LLC acquired a new position in shares of United Therapeutics during the 1st quarter valued at $49,000. Brooklyn Investment Group increased its position in shares of United Therapeutics by 103.2% during the 1st quarter. Brooklyn Investment Group now owns 193 shares of the biotechnology company’s stock valued at $59,000 after purchasing an additional 98 shares during the period. Finally, WPG Advisers LLC acquired a new position in shares of United Therapeutics during the 1st quarter valued at $60,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at United Therapeutics

In other news, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction dated Thursday, August 21st. The stock was sold at an average price of $308.75, for a total value of $3,396,250.00. Following the transaction, the executive vice president directly owned 36,781 shares in the company, valued at approximately $11,356,133.75. The trade was a 23.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Michael Benkowitz sold 22,500 shares of United Therapeutics stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $417.64, for a total value of $9,396,900.00. The disclosure for this sale can be found here. Insiders sold 238,435 shares of company stock worth $93,353,482 over the last quarter. 10.30% of the stock is currently owned by corporate insiders.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR opened at $453.07 on Friday. The business has a 50-day moving average of $356.31 and a two-hundred day moving average of $319.01. The stock has a market capitalization of $20.44 billion, a P/E ratio of 17.68, a P/E/G ratio of 6.76 and a beta of 0.66. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $455.12.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing analysts’ consensus estimates of $6.80 by ($0.39). The business had revenue of $798.60 million during the quarter, compared to the consensus estimate of $802.13 million. United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The company’s revenue for the quarter was up 11.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $5.85 earnings per share. As a group, research analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. JPMorgan Chase & Co. lowered their price target on United Therapeutics from $350.00 to $330.00 and set an “overweight” rating on the stock in a research report on Tuesday, July 8th. Bank of America lifted their price target on United Therapeutics from $314.00 to $463.00 and gave the company a “neutral” rating in a research report on Tuesday, September 2nd. Morgan Stanley lowered their price target on United Therapeutics from $348.00 to $328.00 and set an “equal weight” rating on the stock in a research report on Thursday, July 10th. Oppenheimer lifted their price target on United Therapeutics from $510.00 to $575.00 and gave the company an “outperform” rating in a research report on Friday, September 5th. Finally, Jefferies Financial Group lifted their target price on United Therapeutics from $432.00 to $564.00 and gave the stock a “buy” rating in a report on Tuesday, September 2nd. Ten research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $449.57.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.